Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
10 results
  • Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil. [Clinical Trial]
    Am J Ther. 2002 Nov-Dec; 9(6):476-83.Prisant LM, Black HR, … Weber M
  • An open-label, multicenter, dose-titration study evaluated 2,556 patients with stage I or II essential hypertension (untreated or previously treated with one antihypertensive agent) to assess the effect of a chronotherapeutic formulation of verapamil (Verelan PM) designed to provide maximum plasma concentrations in the midmorning hours. After starting with 200 mg/d at bedtime, the dose of Verelan…
  • Pharmacology of cardiovascular chronotherapeutic agents. [Journal Article]
    Am J Hypertens. 2001 Sep; 14(9 Pt 2):296S-301S.Smith DH
  • Although sudden cardiac death, myocardial infarction, or stroke can occur at any time of day, event rates increase during the waking hours, particularly in the morning. In most people-both normotensive and hypertensive-blood pressure (BP) rises rapidly in the early morning hours, the time when most individuals wake and begin their day. This rise in BP corresponds to increased secretion of catecho…
  • Large-Scale Postmarketing Surveillance of Hypertensive Patients Treated with Verapamil. [Journal Article]
    Am J Ther. 1995 Jul; 2(7):455-461.Cobb MM, Johnson D, … Lefkowitz MP
  • BACKGROUND: In general clinical practice, physicians prescribe calcium channel blockers to a wide range of patients with differing demographic characteristics and hypertension history. This study was undertaken to investigate the effectiveness and safety of sustained-release verapamil (Verelan((R)), verapamil HCl) in patients with essential hypertension, studied under "usual use" conditions. METH…
  • Sustained-release verapamil formulations for treating hypertension. [Clinical Trial]
    J Clin Pharmacol. 1992 May; 32(5):455-62.Frishman WH, Lazar EJ
  • Verapamil, the first calcium-channel blocker to be introduced for clinical use, is a major drug used for the treatment of systemic hypertension. During the past 10 years, the use of verapamil for hypertension has produced a considerable clinical database to support the efficacy and safety of the agent in many patients. Because of its short half-life, verapamil was originally administered 3 to 4 t…
  • Calcium antagonists in cardiology: update on sustained-release drug delivery systems. [Review]
    Clin Cardiol. 1991 Dec; 14(12):947-50.Michelson EL
  • One limitation of standard oral formulations of calcium antagonists has been the need for multiple daily dosing. Sustained-release dosage forms permit simpler regimens and a smoother therapeutic effect. Differences in drug pharmacokinetic and pharmacodynamic properties have led to development of several sustained-release delivery systems. Three major types are available: the osmotic pump, coated …
  • Newer antihypertensive agents. [Review]
    Postgrad Med. 1991 Apr; 89(5):75-81, 84, 89.Rey AM, Grauer K, Gums JG
  • Three recent additions to the list of antihypertensive agents have been approved for use as monotherapy or in combination with other drugs. Betaxolol hydrochloride (Kerlone) maintains its effect for 24 hours, making it a true once-a-day beta blocker. Penbutolol sulfate (Levatol) is as effective as other beta blockers and diuretics. Doxazosin mesylate (Cardura), a selective alpha 1 blocker, also a…
  • Dose proportionality of pharmacokinetics with a cr-verapamil formulation. [Journal Article]
    Eur J Drug Metab Pharmacokinet. 1991; Spec No 3:304-11.Mulligan S, Devane J, Martin M
  • The relatively short half life of verapamil necessitates divided daily dosing in the treatment of angina, hypertension and arrhythmia. To reduce dosing frequency and increase patient compliance and therapeutic efficacy, a controlled-release once-daily verapamil formulation (Verelan) has been developed in three dosage strengths, 120 mg, 240 mg and 360 mg. In order to investigate the dose linearity…
New Search